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Comparison of Corneal Staining with Soflens 66 and 
ACUVUE 2 with AOSept and ReNu Multipurpose 
Solution 
Introduction: 
Recent development and expansion of programmed 
replacement soft contact lenses has provided alternatives to patients 
wearing contact lenses. More lens designs and other options allow 
the doctor and patient to achieve comfort and clarity. Handling of the 
contact lenses has also become easier, as well as a decrease in 
complexity of lens care. Programmed replacement soft contact 
lenses have quickly become a favorite for the doctor and patient. 
These contact lenses are easy to fit, comfortable to wear, and do not 
require the strict cleaning and care as with conventional lenses. 
Contact lens solution advances have been centered around the 
one-step, or one-solution, regimen. These solutions are simple and 
quick to use and are relatively expensive when compared to the 
multi-step solutions. The multi-solution regimen involves complexity 
concerning the steps of cleaning and disinfection and consumes 
more of the patient's time. 
Every contact lens and solution regimen has advantages and 
disadvantages, which include; time of use, ease of use, expense to 
the patient, length of wear time, ocular health, and many other 
aspects. This study probes the health of the cornea by utilizing two 
popular programmed replacement soft contact lenses and two 
commonly used contact lens solutions. 
Comparison of Corneal Staining with Soflens 66 
and ACUVUE 2 with AOSept and ReNu Multiplus 
Multipurpose Solution 
Study Objectives: 
The purpose of this study was to evaluate the incidence and patterns of corneal 
staining on 40 subjects wearing two FDA-approved soft lenses (ACUVUE 2 and 
Soflens 66) while using two FDA-approved soft lens care regimens (B&L ReNu 
Multi-Plus Multi-Purpose and ClBA AOSept Lens Care System.) 
Study Design: 
The study was a randomized contralateral design in which subjects were fitted 
with a Vistakon ACUVUE 2 soft lens on one eye and a Bausch and Lomb Soflens 
66 on the fellow eye. The subjects were instructed to wear the lenses, on a daily 
wear basis, for a minimum of 10 hours a day. 
Twenty random subjects were placed on the B&L ReNu Multi-Plus Multi-Purpose 
Solution and 20 subjects on the ClBA AOSept Lens Care System for one month. 
The subjects were given oral and written instructions on the proper use of each 
lens care system as outlined in the manufactures packages inserts. The subjects 
were evaluated for corneal staining as well as bulbar and tarsal conjunctival 
hyperemia at intervals; 
Dispensing Visit 
One week 
Two weeks 
Four weeks 
At the end of one month there was a three-day "washout" period of no lens wear 
prior to switching the lens care regimens. The subjects were reexamined and 
new baseline data established. The subjects were then instructed to begin new 
soft lenses, wearing the lenses (ACUVUE 2 and Soflens 66) on the same eyes 
as throughout the first month. The subjects were carefully instructed on the use 
of the new lens care regimen and evaluated for corneal staining and conjunctival 
inflammation following the same protocol as used throughout the first month. 
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STUDY MATERIALS 
ACUVUE 2 (Vistakon) 
1. FDA Group: 
2. Material: 
3. Water Content: 
4. Tint: 
5. Manufacturing Process: 
6. Dk: 
7. Wearing Mode: 
8. Disinfection Method: 
9. Base Curves: 
10. Powers: 
I 1. Diameter: 
12. Center Thickness: 
13. UV Blocker: 
Soflens 66 (Bausch & Lomb) 
I. FDA Group: 
2. Material: 
3. Water Content: 
4. Tint: 
5. Manufacturing Process: 
6. Dk: 
7. Wearing Mode: 
8. Disinfection Method: 
9. Base Curves: 
I 0. Powers: 
1 I. Diameter: 
12. Center Thickness: 
13. UV Blocker: 
Group 4 
(High Water > 50% Water, Ionic Polymer) 
etafilcon A 
58% 
Light Blue Visibility Tint 
Stabilized Soft Molding 
28 
Daily or Extended Wear 
Chemical or Hydrogen Peroxide 
8.3 and 8.7 mm 
+0.50 to +8.00 and -0.50 to -12.00 
14.0 mm 
.084mm (-3.00) and .17mm (+3.00) 
Yes 
Group 2 
(High Water > 50% Water, Nonionic Polymers) 
alphafilcon A 
66% 
Light Blue Handling Tint 
Case Molded 
32 
Daily or Extended Wear 
Heat, Chemical or Hydrogen Peroxide 
Flat I Medium and Steep I Medium 
+0.50 to +6.00 and -0.50 to -9.00 
14.2 mm 
.I 0 (-3.00) 
No 
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STUDY SOLUTIONS 
Bausch & Lomb ReNu Multiplus Multi-Purpose Solution 
The Bausch & Lomb ReNu Multiplus Multi-Purpose Solution is a sterile, isotonic 
multi-purpose disinfection solution that contains sodium chloride, sodium borate, 
edetate disodium, and boric acid as well as the active ingredients of: 
1. Poloxamine, for removal of lipid and environmental debris. 
2. Dymed (polyamino-propyl biguanide 0.0001 %), as the preservative 1 
disinfectant. 
3. Hydrante (hydroxyalkyl phosphorate), for daily protein removal. 
Ciba Vision AOSept 
The Ciba Vision AOSept is a hydrogen peroxide based system that consists of: 
I. MiraFlow Extra-Strength Daily Cleaner (1 5.7% isopropyl alcohol, 
poloxamer 407, amphoteric 10) for daily cleaning. 
2. SoftWear Saline, (a sterile, isotonic saline solution preserved with sodium 
perborate, generating up to 0.006% hydrogen peroxid.e), for rinsing. 
3. AOSept (3% Hydrogen Peroxide), for disinfection. 
4. A 0  Disc, Platinum coated disc for neutralization of the peroxide. 
5. A 0  Lens Holder and Cup, the A 0  Disc neutralizer is attached to the stem of 
the lens holder and placed into the lens cup for disinfection. 
Allergan Lens Plus Rewetting Drop 
1. Preservative free rewetting drop in single use .O1 oz. vials 
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ELIGIBILITY CRITERIA 
Inclusion Criteria 
Prior to consideration for this clinical investigation, each prospective subject must 
have met the following conditions: 
1. The subject must have been at least 18 years of age. 
2. The subject must have had no known ocular or systemic allergies which might 
interfere with contact lens wear. 
3. The subject must have had no known systemic disease, or need for 
medication, which might interfere with contact lens wear, i.e. antihistamines. 
4. The subject must have had normal eyes (no ocular medications or ocular 
infection of any type). 
5. The subject must have had a visual acuity best correctable to 20125 for each 
eye. 
6. The subject must have been spherically correctable to a distance visual acuity 
of 20130 or better for each eye. 
7. The subject must have read and sign the Statement of Informed Consent and 
be provided with a copy of this form. 
8. The subject must have appear able and willing to adhere to the instructions 
set forth in this clinical protocol. 
9. The subject, based on their knowledge, must NOT have been pregnant or 
lactating at the time of enrollment. 
10.The subject, based on their knowledge, must NOT have had an infectious 
disease (e.g., hepatitis, tuberculosis) or an immunosuppressive disease (e.g., 
HIV). 
11 .The subject, based on their knowledge, must NOT have been diabetic. 
12.The subject must not have had greater than two regions of the cornea with 
greater than a grade I type staining and no one region of grade I type staining 
which covers greater than 30% of that particular quadrant. 
13.The subject must not have had more than 1.00D of refractive astigmatism. 
14. The subject must have had a contact lens prescription between -1.50D and 
-9.00 D. 
15. The subject must have been corrected to 20130 or better in each eye and 
satisfied with the vision and comfort of each lens. 
16.The subject must have been a current soft contact lens wearer (daily wear or 
extended wear). 
In an effort to standardize the sample population of subjects for this investigation, 
it was essential that subjects be carefully screened for any atypical condition. 
Therefore, in addition to satisfying the above criteria, subjects undetwent a 
complete ocular examination to ensure that none of the contraindications 
described below applied before being considered eligible to participate in this 
study. 
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Exclusion Criteria 
No subject was entered into this study who was known to have or currently 
exhibited any of the following conditions: 
1. Ocular or systemic allergies which might interfere with contact lens wear. 
2. Systemic disease or use of medication which might interfere with contact lens 
wear. 
3. Clinically significant (grade 3 or 4) corneal edema, corneal vascularization, 
corneal staining, bulbar hyperemia, tarsal hyperemia or any other abnormality 
of the cornea which might cause unsafe contact lens wear (see SLIT LAMP 
FINDINGS GRADING SCALE). 
4. Any active ocular infection. 
5. Any corneal distortion resulting from previous hard contact lens wear. 
6. Pregnancy or lactation. 
CONFIDENTIAL 
EXPERIMENTAL DESIGN: 
Candidates for this study were screened from the outpatient clinic at Pacific 
University College of Optometry in Forest Grove Oregon. All candidates for the 
study were required to have undergone a complete, dilated ocular examination 
within the past six months. Subjects were requested to have not worn their 
contact lenses 72 hours prior to the initial study examination. Subject eligibility 
was established at the Initial Visit Examination and a total of 40 subjects were 
selected. The subjects were required to meet all of the previously described 
inclusion criteria to be considered eligible for this study. 
A modified ocular examination was performed at the Initial Visit, which include 
the following; 
a detailed patient history 
habitual contact lenses and solutions 
best corrected spectacle Rx and high contrast Snellen acuity's 
keratometry, with notation of mire clarity 
slit lamp examination, white light (Slit Lamp Finding Grading Scale) 
corneal staining evaluation with fluorescein 
At the Initial Visit the type, area and depth of corneal staining were evaluated 
with the cobalt light of the slit lamp and a # I  2 Kodak wratten filter. The 
fluorescein used throughout the study was Minims 1 %, which is a non-preserved 
solution manufactured by Chauvin Pharmaceuticals Ltd. Throughout the 
course of the study, the investigator grading the slit lamp findings and 
corneal staining patterns, was masked to the lenses worn on each eye and 
the care regimen being used. 
The fluorescein staining procedure was as follows: 
1. One drop of sodium fluorescein was instilled into the inferior cul-de-sac of 
the subject's right eye and the patient was instructed to blink a few times. 
2. The slit lamp beam was set to a width of 2.0 mm and a height of 6.0 mm 
(approximately half the diameter of the cornea) and the cornea viewed at 
a magnification of 16X. 
3. The central 6.0 mm circular region of the cornea was estimated using the 
slit beam. 
4. The epithelial staining was graded and recorded using the scale below. If 
a region had more than one type or depth of staining, the greatest amount 
of staining was graded and recorded. 
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5. A picture of the staining (if any) was drawn in the appropriate area on the 
Patient Visit Forms in the Corneal Staining Template. The Corneal 
Staining Template was divided into five regions: 
1. Central 
2. Nasal 
3. Temporal 
4. Inferior 
5. Superior 
6. The above steps were repeated for the subject's left eye 
Superficial Punctate Keratitis (SPK) 
Throughout the course of the study Superficial Punctate Keratitis was defined as: 
any type of staining in all five regions quadrants of the cornea, 
or 
any type of staining in at least three quadrants in addition to 
(type 2) in at least one quadrant 
(type 3) in at least one quadrant 
(type 4) in at least one quadrant 
Superficial Punctate Keratitis (Suspect) 
Throughout the study Superficial Punctate Keratitis (Suspect) was defined as: 
type 1 staining in four quadrants of the cornea with no other type of staining in 
the fifth quadrant. 
or 
any type of staining in three quadrants. 
None (No Punctate Staining) 
no staining in any quadrant 
or 
any type of staining in only one or two quadrants. 
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Fluorescein Grading Scales 
Type: 
0 = none 
1 = micropunctate 
2 = macropunctate 
3 = coalesced macropunctate 
4 = patch (> 1 mm) 
Area: 
0 = less than 5 micropunctate or macropunctate spots. The type of staining 
was recorded as either micropunctate or macropunctate. 
Imagine a border enclosing the area of staining and estimate the area of 
staining per region from this perspective. If the staining is distributed 
throughout the region of interest (e.g. in two distinct parts of the region) 
add the areas of staining and record the sum (e.g. 10% +20% = 30%) 
If the staining is micropunctate or macropunctate with less than 10 spots 
spread over a region, decrease the area score by "collapsing the spots". 
This will allow the area score to accurately reflect the clinical findings. 
Scale 
0 = 0% of region covered 
1 = 10% of region covered 
2 = 20% of region covered 
3 = 30% of region covered 
4 = 40% of region covered 
5 = 50% of region covered 
6 = 60% of region covered 
7 = 70% of region covered 
8 = 80% of region covered 
9 = 90% of region covered 
10 = 100% of region covered 
Depth 
0 = None 
1 = Superficial epithelial 
2 = Full epithelial 
3 = Stromal glow 
If the subject was deemed eligible, the monitors explained in detail the nature of 
the study and the patient's requirements for participation in the two month study. 
Interested subjects were asked to read the Statement of Informed Consent Form 
CONFIDENTIAL 9 
and the principal investigators andlor the study monitors answered any and all 
questions. All participants were required to sign both copies of the Statement of 
Informed Consent Form and were provided a copy of the consent form. Eligible 
subjects were asked to complete a subjective questionnaire rating various 
aspects of the comfort, dryness, grittiness and visual acuity of their habitual 
lenses. 
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DIAGNOSTIC FITTING AND LENS DISPENSING 
All eligible subjects were diagnostically fitted with ACUVUE 2 and Soflens 66 
lenses from the lens inventory at Pacific University. 
Study Lens Parameters: 
ACUVUE 2: Base Curves: 8.3 and 8.7 mm 
Powers -1.50 to -9.00 D. 
Diameter 14.0 mm 
Soflens 66: Base Curves: FlatIMedium and SteepIMedium 
Powers -1.50 to -9.00 D. 
Diameter 14.2 mm 
20 subjects were randomly fitted with the ACUVUE 2 lens on the right eye 
and the Soflens 66 on the left eye and, 
20 subjects were randomly fitted with the Soflens 66 lens on the right eye and 
the ACUVUE 2 on the left eye. 
Subjects were instructed to wear the appropriate lenses in the appropriate eyes 
throughout the course of the two-month study. 
Once the optimum lens fit has been established on the appropriate eyes, the 
subjects were randomly dispensed one of the two lens care regimens: 
20 subjects received the B&L ReNu Multi-Plus Multi-Purpose Solution and, 
20 subjects received the ClBA AOSept Lens Care Solution 
Detailed oral and written instructions were given to each subject describing the 
manufactures suggested lens care regimen as described in the B&L ReNu Multi- 
Plus Multi-Purpose Solution and ClBA AOSept Lens Care Solution, package 
inserts. No enzyme cleaning products was used on either soft lens throughout 
the course of this study. 
After 30 minutes of lens wear, the subjects were asked to complete a subjective 
questionnaire rating the baseline comfort, dryness and grittiness of the lenses. 
Subjects were instructed to: 
soak their lenses a minimum of 8 hours a night. 
to wear their lenses a minimum of 10 hours a day. 
to always place the contact lenses (ACUVUE 2 and Soflens 66) on the pre- 
selected eyes throughout the course of the one-month evaluation. 
wear the same pair of lenses throughout the course of the one-month study 
(no lens disposal). 
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return for regularly scheduled follow-up visits at one week, two weeks and 
four weeks. 
immediately report any abnormalities i.e. ocular complications, lost or 
damaged lenses, to the investigators or monitors. 
If for some reason a lens needed to be replaced e.g. due to loss or damage, both 
the right and the left study lenses were replaced as a pair. This ensured that the 
data collected for the pair of study lenses at the next visit was obtained from 
lenses of the same age. 
ONE WEEK FOLLOW-UP VISIT 
At the I-week follow-up visit, the subjects subjective symptoms since their last 
visit and 30 minutes post lens removal were recorded. Subjects were again 
asked to complete a questionnaire rating the subjective comfort, dryness and 
grittiness of the lenses. A detailed slit lamp examination was performed by one 
of the monitors to verify that the patient had not inadvertently switched the lenses 
and to assess the surface quality and fitting characteristics of each lens. 
Switched Lenses 
If the lenses have been switched, the data from that visit was not analyzed. 
If no corneal staining was present, the patient was requested to begin the 
lenses on the appropriate eyes and return for a new scheduled follow-up visit. 
If corneal staining (greater than baseline) was present, the patient was 
discontinued from the lenses for two days or until the staining had resolved. 
Following resolution, the patient was asked to begin wearing the lenses on 
the appropriate eyes and requested to return for a new scheduled follow-up 
visit. 
The lenses were then removed by one of the study monitors. The investigators 
than performed slit lamp biomicroscopy to evaluate ocular health using the FDA 
Slit Lamp Finding Classification Scale. The type, area and depth of corneal 
staining were evaluated with the cobalt light of the slit lamp and a # I 2  Kodak 
wratten filter as previously described. The eyes were then rinsed, the lenses re- 
inserted and the subject requested to return for follow-up in one week. 
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TWO WEEK AND FOUR WEEK FOLLOW-UP VISITS 
The 2-week and 4-week follow-up visits followed the same protocol as the 1- 
week follow-up visit. 
Throughout the course of the study, a subject may have needed to be 
discontinued from lens wear for reasons such as, unilateral lens intolerance or 
excessive corneal staining. If excessive corneal staining was present the 
patient was asked to discontinued lens wear for 2 days or until the staining has 
resolved. Following resolution, the subjects fellow eye lens type was fitted to 
the problem eye and subject requested to begin the new lens on the 
problematic eye. The subject was asked to continue the present lens on the non- 
problematic eye and continue the remaining course of the study. Data from the 
new lens was not analyzed. 
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PHASE #2, SOLUTION CROSSOVER 
At the end of one month there was a three-day "washout" period of no lens wear 
prior to switching the lens care regimens. The subjects were asked to complete 
the subjective questionnaire and a detailed slit lamp examination performed to 
quantify corneal health, conjunctival inflammation and corneal staining. 
If the corneas were free of staining the subject was instructed to immediately 
begin new soft lenses, wearing the lenses on the same eyes as in the 
previous month. If any significant slit lamp findings were present (greater than 
baseline examination) lens wear was discontinued for a maximum of 3 days. At 
that time, a new baseline for corneal staining was established. 
The subjects were carefully instructed (oral and written) on the use of the new 
lens care regimen. 
Subjects were instructed to: 
soak their lenses a minimum of 8 hours a night. 
to wear their lenses on a minimum of 10 hours a day. 
to always place the contact lenses (ACUVUE 2 and Soflens 66) on the same 
eyes as throughout the first month evaluation. 
wear the same pair of lenses throughout the course of the one-month study 
(no lens disposal). 
return for regularly scheduled follow-up visits at one week, two weeks and 
four weeks. 
immediately report any abnormalities i.e. ocular complications, lost or 
damaged lenses, to the investigators or monitors. 
The subject's participation in this study was concluded following the completion 
of the second four week visit. At that time all the patient's remaining study 
materials (lenses and solutions) were returned to the investigators. 
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STUDY RESULTS 
Cohort Population 
The cohort population were those subjects who's data were considered for 
analysis. To be included in the cohort population the subject must have: 
completed all of the scheduled visits throughout the course of the two month 
study or, 
completed matched portions of the study i.e. one week or two week visits with 
each solution, (B&L ReNu Multi-Plus Multi-Purpose Solution and ClBA 
AOSept Lens Care System). 
Cohort Patient Demographics 
40 subjects were enrolled and 34 subjects were considered cohort, throughout 
the course of the two-month study. Of the 34 cohort subjects who participated in 
the study: 
(49 $4) were male 
(51 %)were female 
The mean age was 23 years with a range of 22 to 26 years. 
Non-Cohort Population 
The non-cohort population were those subjects whose data were not considered 
for analysis. 
Subject Visit Reason Discontinued 
#26 Phase I, 4 week visit Discontinued for non-study related 
reasons. 
#40 Phase 1, Enrollment visit Persistent staining at enrollment visits, 
subject discontinued from study 
#20 Phase II, Baseline visit SPK at beginning of Phase II 
#22 Phase II, Baseline visit SPK at beginning of Phase II 
#25 Phase II, Baseline visit SPK at beginning of Phase II 
#30 Phase II, Baseline visit SPK at beginning of Phase II 
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Cohort Population 
The cohort population were those subjects whose complete or partial data were 
considered for analysis. The following reasons were sited for subjects 
discontinued or with incomplete data throughout the course of the two month 
study. 
Subject Visit Reason Discontinued or Incomplete Data 
#39 Phase 1, 1 week visit No one week data due to non-study 
related, corneal abrasion. 
#8 Phase I, 4 week visit Incomplete due to torn lens with AOSept 
Care System. 
#24 Phase I, 4 week visit Incomplete due to torn lens with AOSept 
Care System. 
#27 Phase I, 4 week visit Incomplete due to non-study related 
reasons. 
#38 Phase I, 4 week visit Incomplete due to non-study related 
reasons. 
#I 9 Phase 2, 2 week visit Incomplete due to non-study related 
reasons. 
Phase 2, 4 week visit Incomplete due to non-study related 
reasons. 
#38 Phase 2, 2 week visit Incomplete due to non-study related 
reasons. 
#23 Phase 2, 4 week visit Incomplete due to torn lens with AOSept 
Care System. 
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Results 
Introduction 
Slit lamp examination provided three categories of subject-objective data for 
each of the five quadrants for each of the subject's eyes: 
type of staining 
depth of staining 
area of staining. 
In addition, type of staining was evaluated across all quadrants to determine if 
the patient had developed Superficial Punctate Keratitis (SPK) or was a Suspect 
for developing SPK. 
The type of corneal staining was graded from 0 to 4, and depth of staining was 
graded from 0 to 3, according to the clinically-relevant rating scales described 
previously. Even though numbers are employed to allow quick description of the 
findings, these rating scales are non-parametric, in that the number of grades is 
limited and the intervals between the grades are unequal as one progresses up 
the scale. Consequently, it is inappropriate to evaluate differences or changes in 
these data using parametric analyses, such as means, standard deviations, t- 
tests, analyses of variance, etc. 
The multidimensional chi-square ( x ~ )  analysis (Sheskin, 2000) was chosen as the 
statistical tool to evaluate type and depth of staining. This is a test of population 
differences where multiple dependent or independent factors may influence the 
results. In this study, these factors include: 
the lens care regimen used (AOSept or ReNu), 
the contact lens worn (Acuvue 2 or Soflens 66), and 
the exam visit (Dispensing, 1 Week, 2 Weeks, and 4 Weeks). 
The area of corneal staining was graded on an eleven-point scale, from 0 to 10, 
which corresponds directly to the percentage of the quadrant area stained, from 
0% to 100%. These data are parametric, and they were evaluated using the 
repeated-measures analysis of variance (ANOVA) test. The factors analyzed are 
the same as those for type and depth of staining, in addition to the quadrant 
evaluated (Central, Nasal, Temporal, Inferior, and Superior). 
Presence of SPK was determined by counting the number of quadrants showing 
staining as well as the type of staining in those quadrants. It was categorized as 
either: 
None, 
SPK Suspect, or 
SPK, 
as per the previously described definitions. Once again, the multidimensional X2 
analysis was used to evaluate the data, with factors of lens care regimen and 
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exam visit. In addition, the Bowker test of symmetry (Sheskin, 2000) was 
employed to compare placement of subjects in SPK categories for each cleaning 
regimen at comparable exam visits. The resulting test statistic, X2, is the same as 
that used to assess population differences. 
However, one drawback of the Bowker test is the inability to effectively analyze 
multiple factors simultaneously, requiring separate analyses, for example, for 
each of the four exam visits. Since these multiple analyses are based on data 
that were collected as repeated measures of the same subjects, the level of 
statistical significance, p, must be reduced by the number of analyses performed. 
Otherwise, a non-significant result may appear to be significant solely by chance; 
recall that the typical significance level of p = 0.05 assumes that there is a 1 in 
20, or 5%, chance that the result for the test of significance is incorrect. Thus, for 
the Bowker tests, the significance level used is p = 0.05 / 4 = 0.0125. For all 
other tests, the typical level of p = 0.05 is used. 
Number of Subjects 
The present study began with 40 subjects. For the reasons described above, 
several subjects dropped out or were removed over the two-month test period. 
However, the experimental design allowed each subject to act as his or her own 
control. Consequently, the subject's data were included in the analyses if 
comparable exam visits were kept during both phases of the study. For example, 
if a subject made all four exam visits in Phase I, but missed the 4 Week visit in 
Phase II, only the 4 Week visit of Phase I was discounted, rather than the entire 
data set for the subject. 
As a result, data are reported for: 
34 subjects for the Dispensing visit, 
33 subjects for the 1 Week visit, 
31 subjects for the 2 Week visit, and 
28 subjects for the 4 Week visit. 
The chi-square test, used to analyze type and depth of staining and part of the 
SPK data, is designed to evaluate populations with unequal numbers. For the 
other analysis of the SPK data, the Bowker test, by its nature, evaluates matched 
pairs of data. Therefore, no manipulation or adjustment of the data is necessary 
to perform any of these analyses properly. 
On the other hand, the ANOVA test, used to analyze area of staining, assumes 
that all conditions contain the same number of data values. Since a critical 
consideration in the present study is the effect over time, as measured at the 
different exam visits, some accommodation must be made for the missing data. 
Two possible solutions may be employed. First, all data may be deleted from 
both phases of the study from any subject who missed one or more visits; this 
results in a remaining total of 30 subjects. The second option is to insert for each 
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missing data point the mean value of the actual data collected in that condition. 
Note that the mean value of the data with the inserted values does not change 
from the original, and that the standard deviation varies only slightly, especially if 
only a small proportion of values are inserted in this manner. For completeness, 
both of these analyses are reported below. 
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Type of Corneal Staining 
Throughout the course of the study, the type of corneal staining was graded and 
defined as: 
0 = none 
1 = micropunctate 
2 = macropunctate 
3 = coalesced macropunctate 
4 = patch (> 1 mm) 
The multidimensional chi-square (X2) analysis (Sheskin, 2000) was chosen as the 
statistical tool to evaluate type of staining. This is a test of population differences 
where multiple dependent or independent factors may influence the results. In 
this study, these factors include: 
the lens care regimen used (AOSept or ReNu), 
the contact lens worn (Acuvue 2 or Soflens 66), and 
the exam visit (Dispensing, I Week, 2 Weeks, and 4 Weeks). 
The total number of quadrants exhibiting each grade of staining was calculated 
for each condition of cleaning regimen, contact lens, and exam visit (see Table 
1). Staining separated into the five quadrants was not evaluated, since it would 
have added unnecessary complexity to this analysis and since the area of 
staining analysis revealed no significant effect of the quadrants (see below). 
Nevertheless, visual inspection of the raw suggests that type of staining is 
roughly similar in all four peripheral quadrants and possibly slightly lower in the 
central quadrant. 
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Using Table I, an overall interaction effect, given by the omnibus X2 analysis, 
reveals that the data do not represent equivalent results, X2 (70) = 414.7, p = 0. 
Based on this table, the main effects also were calculated, where each factor 
was evaluated without regard to the other factors. There is a significant 
difference between: 
exam visits, X2 (12) = 134.8, p = 0, and 
lens care regimens, X2 (4) = 124.3, p = 0, 
however, no difference between contact lenses, X2 (4) = 2.48, p = 0.649. 
When considering each factor with regard to the other factors, there is a 
significant difference between: 
the types of staining, X2 (60) = 414.7, p = 0, 
exam visits, X2 (57) = 233.8, p = 0, 
lenscare regimens, X2 (39) = 196.5, p = 0, 
however, no difference between contact lenses, X2 (39) = 25.7, p = 0.950. 
Figure 1 shows the total number of quadrants with type 2 staining or greater for 
each care regimen and contact lens combination at each exam visit. Figure 2 
shows the percentage of quadrants with type 2 staining or greater under the 
same conditions. 
The total number and percentage of subjects with type 2 staining or greater is 
shown in Table 2. Figure 3 shows the total number of subjects with type 2 
staining or greater for each lens care regimen and contact lens combination at 
each exam visit. Figure 4 shows the percentage of subjects with type 2 staining 
or greater under the same conditions. 
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Table 1. Total number of eve quadrants exhibiting type of staining (0-4) for 
each condition of: 
lens care regimen (AOSept or ReNu), 
contact lens (Acuvue 2 or Soflens 66), and 
exam visit (Dispense, 1 Week, 2 Week, and 4 Week). 
DlSP 1 WK w 
A2 BL66 A2 I BL66 A2 I BL66 A2 I BL66 
AOSEPT 
Table 2. Total number and percentage of subiects exhibiting type 2 staining 
or greater for each condition of: 
lens care regimen (AOSept or ReNu), 
contact lens (Acuvue 2 [A21 or Soflens 66 [BL 661)) and 
exam visit (Dispense, 1 Week, 2 Week, and 4 Week). 
TOTAL 
QUADRAN 
n 
TS, 
VISIT 
Figure 1. Shows the total number of quadrants with type 2 staining o r  
greaterfor each care regimen and contact lens combination at 
each exam visit. 
I TOTAL 
QUADRAN 
Yo 
AOSEPT - BL 66 
VISIT 4 WK 
Figure 2. Shows the percentage of quadrants with type 2 staining o r  
greaterfor each care regimen and contact lens combination at 
each exam visit. 
PATIENTS, 
n 
Figure 3. Shows the total number of subiects with type 2 staining or greater 
for each care regimen and contact lens combination at each exam 
visit. 
1 PATIENTS, 
OSEPT - BL 66 
AOSEPT - A2 
VISIT 4 WK 
Figure 4. Shows the percentaae of subiects with type 2 staining or greater 
for each care regimen and contact lens combination at each exam 
visit. 
Depth of Corneal Staining 
Throughout the course of the study the depth of corneal staining was graded and 
defined as: 
0 = None 
I = Superficial epithelial 
2 = Full epithelial 
3 = Stromal glow 
4: Patch (>= 1 rnrn) 
&(record in full units only) 
O:O% 1:10% 2:20% 
3: 30% 4: 40% 5: 50% 
6: 60% 7: 70% 8: 80% 
9: 90% 10: 100% 
1 : Superficial Epithelial 
2: Full Epithelial 
3: Strornal Glow 
Again, the multidimensional chi-square (X2) analysis (Sheskin, 2000) was chosen 
as the statistical tool to evaluate depth of staining. The factors which influenced 
the depth of staining results include: 
the lens care regimen used (AOSept or ReNu), 
the contact lens worn (Acuvue 2 or Soflens 66), and 
the exam visit (Dispensing, 1 Week, 2 Weeks, and 4 Weeks). 
The total number of quadrants exhibiting each grade of staining was calculated 
for each condition of lens care regimen, contact lens, and exam visit (see Table 
3). As with type of staining, depth of staining was not evaluated in each of the 
five quadrants. This would have added unnecessary complexity to this analysis 
and since the area of staining analysis revealed no significant effect of the 
quadrants (see below). Nevertheless, visual inspection of the raw suggests that 
depth of staining is roughly similar in all four peripheral quadrants and possibly 
slightly lower in the central quadrant. 
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Using Table 3, an overall interaction effect, given by the omnibus X2 analysis, 
reveals that the data do not represent equivalent results, X2 (55) = 418.2, p = 0. 
Based on this table, the main effects also were calculated, where each factor 
was evaluated without regard to the other factors. There is a significant 
difference between: 
exam visits, X2 (9) = 130.7, p = 0, and 
care regimens, X2 (3) = 144.1, p = 0, 
however, no difference between contact lenses, (3) = 3.14, p = 0.371. 
When considering each factor with regard to the other factors, there is a 
significant difference between: 
the depth grades of staining, X2 (45) = 418.2, p = 0, 
exam visits, (45) = 21 1.3, p = 0, and 
care regimens, (31) = 197.9, p = 0, 
however, no difference between contact lenses, X2 (31) = 32.8, p = 0.377. 
Figure 5 shows the total number of quadrants with grade 2 staining depth or 
greater for each care regimen and contact lens combination at each exam visit. 
Figure 6 shows the percentage of quadrants with grade 2 staining depth or 
greater under the same conditions. 
The total number and percentage of subjects with grade 2 staining depth or 
greater is shown in Table 4. Figure 7 shows the total number of subjects with 
grade 2 staining depth or greater for each care regimen and contact lens 
combination at each exam visit. Figure 8 shows the percentage of subjects with 
grade 2 staining depth or greater under the same conditions. 
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Table 4. Total number and percentage of subjects exhibiting grade 2 
staining depth or greater for each condition of: 
lens care regimen (AOSept or ReNu), 
contact lens (Acuvue 2 [A21 or Soflens 66 [BL 66]), and 
exam visit (Dispense, 1 Week, 2 Week, and 4 Week). 
TOTAL 
QUADRANTS, 
Figure 5. Shrws the total number of auadrants with grade 2 staining depth 
or!  reaterfor each care regimen and contact lens combination at 32 
eat 1: exam visit. 
1 TOTAL 1 QUADRANTS, 
% 
AOSEPT - BL 66 
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Figure 6. Shows the percentase of auadrants with grade 2 staining depth 
or greater for each care regimen and contact lens combination at 
each exam visit 

1 PATIENTS, 
Figure 8. Shows the percentaqe of subiects with grade 2 staining depth or 
greaterfor each care regimen and contact lens combination at 
each exam visit. 
Area of Corneal Staining 
Throughout the course of the study the area of corneal staining was graded and 
defined as: 
Scale 
0 = 0% of region covered 
1 = 10%ofregioncovered 
2 = 20% of region covered 
3 = 30% of region covered 
4 = 40% of region covered 
5 = 50% of region covered 
6 = 60% of region covered 
7 = 70% of region covered 
8 = 80% of region covered 
9 = 90% of region covered 
10 = 100% of region covered 
O:O% 1:10% 2:20% 
3: 30% 4: 40% 5: 50% 
6: 60% 7: 70% 8: 80% 
9: 90% 10: 100% 
1: Superficial Epithelial 
2: Full Epithelial 
3: Stromal Glow 
The area of staining was graded on an eleven-point scale, from 0 to 10, which 
corresponds directly to the percentage of the quadrant area stained, from 0% to 
100%. These data are parametric, and they were evaluated using the repeated- 
measures analysis of variance (ANOVA) test. The factors analyzed are the same 
as those for type and depth of staining, in addition to the quadrant evaluated 
(Central, Nasal, Temporal, Inferior, and Superior). 
Baseline analysis of area of staining at the dispensing visits for both phases of 
the study shows that there are no significant differences between: 
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the eyes of the subjects, F(1,24) = 0.01, p = 1.00, 
quadrants of the eyes, F(4,24) = 0.92, p = 0.468, or 
phases of the study, F(1,636) = 2.80, p = 0.095. 
Likewise, there are no significant interaction effects between any of the following 
factors: 
eyes and quadrants, F(4,24) = 0.01, p = 1.000, 
eyes and phases, F(1,636) = 2.07, p = 1.000, 
quadrants and phases, F(4,636) = 0.49, p = 0.743, and 
eyes and quadrants and phases, F(4,636) = I .75, p = 0.1 37. 
Table 5 shows the maximum area of staining for any quadrant under all test 
conditions. Analysis of all data, including quadrants, was conducted first by 
removing all values for any subjects who had missing data points, resulting in a 
total of 30 subjects. These data show that there is a significant effect of: 
lens care regimen, F(1,16) = 5.82, p = 0.028. 
However, there are no significant effects of: 
exam visit, F(3,8) = 2.19, p = 0.101, 
contact lenses, F(1,46) = 0.08, p = 0.783, or 
quadrants of the eye, F(4,16) = 0.56, p = 0.695, 
or any other interactions of factors. 
The data were analyzed again by inserting mean values for missing data, such 
that the total number of subjects remained at 38. As before, this shows that there 
are significant effects of: 
lens care regimen, F(1,28) = 13.7, p = 0.000, 
exam visit, F(3,84) = 5.03, p = 0.003, and 
the interaction of regimen and visit, F(3,84) = 4.62, 0.005. 
Similarly, there are no significant effects of: 
contact lenses, F(1,28) = 0.04, p = 0.849, 
quadrants of the eye, F(4,28) = I .16, p = 0.351, 
or any other interactions of factors. 
Figure 9 shows the mean staining area of a quadrant, in percent, for each 
cleaning regimen and contact lens combination at each exam visit. Figure 10 
shows the total number quadrants under each condition that presented with area 
of staining of grade 3 (30%) or higher. Figure 11 shows the percentage of 
quadrants under each condition that presented with area of staining of grade 3 or 
higher. Figure 12 shows the total number of subjects under each condition who 
presented with area of staining of grade 3 or higher in at least one eye. Figure 
13 shows the percentage of patients under each condition who presented with 
area of staining of grade 3 or higher in at least one eye. 
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MAX STAINING AREA 
Table 5. Maximum area of staining for any quadrant for each condition of: 
lens care regimen (AOSept or ReNu), 
contact lens (Acuvue 2 [A21 or Soflens 66 [BL 66]), and 
exam visit (Dispense, 1 Week, 2 Week, and 4 Week). 
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Figure 13. Shows the percentage of patients under each condition who 
presented with area of staining of grade 3 or higher in at least one 
eye. 
Superficial Punctate Keratitis, Definitions 
Superficial Punctate Keratitis 
Throughout the course of the study Superficial Punctate Keratitis was defined as: 
any type of staining in all five quadrants, 
or 
any type of staining in at least three quadrants in addition to: 
type 2 
type 3 
type 4 staining in at least one other quadrant. 
Superficial Punctate Keratitis (Suspect) 
Throughout the course of the study Superficial Punctate Keratitis (Suspect) was 
defined as: 
type 1 staining in four quadrants with no staining in the fifth quadrant, 
or 
any type of staining in three quadrants. 
None (No Punctate Keratitis) 
Throughout the course of the study No Punctate Keratitis was defined as: 
no staining in any quadrant, 
or 
any type of staining in only one or two quadrants. 
Justification 
Literal interpretation of the previous definitions would miss or incorrectly identify: 
SPK in patients with type 2 or greater staining in more than two quadrants, 
together type I staining in the remaining quadrant(s), 
SPK Suspect in patient's with greater than type 1 staining in any of three 
quadrants, together with no staining in the fourth and fifth quadrants. 
CONFIDENTIAL 
Superficial Punctate Keratitis Results 
Presence of SPK was determined by counting the number of quadrants showing 
staining as well as the type of staining in those quadrants. It was categorized as 
either: 
None, 
SPK Suspect, or 
SPK, 
as per the previously described definitions. Once again, the multidimensional X2 
analysis was used to evaluate the data, with factors of lens care regimen and 
exam visit. In addition, the Bowker test of symmetry (Sheskin, 2000) was 
employed to compare placement of subjects in SPK categories for each cleaning 
regimen at comparable exam visits. The resulting test statistic, x2, is the same 
as that used to assess population differences. 
The data were organized by the highest category of either eye for each subject. 
In addition, cleaning regimen was considered with regard to the phase of the 
study (see Table 6). 
Using Table 6, an overall interaction effect, given by the omnibus X2 analysis, 
reveals that the data do not represent equivalent results, X2 (39) = 112.4, p = 0. 
Based on this table, the main effects also were calculated, where each factor 
was evaluated without regard to the other factors. There is a significant 
difference between: 
exam visits, X2 (6) = 26.5, p = 0.000, 
care regimens, x2 (2) = 43.4, p = 0, 
however, no difference between study phases, X2 (2) = 0.24, p = 0.866. 
When considering each factor with regard to the other factors, there is a 
significant difference between: 
SPK categories, X2 (30) = 107.6, p = 0, 
exam visits, X2 (33) = 660.8, p = 0.002, and 
lens care regimens over phases, X2 (33) = 79.4, p = 0. 
Figure 14 shows the total number of eyes with SPK or SPK Suspect for each 
lens care regimen and phase combination at each exam visit. Figure 15 shows 
the percentage of eyes with SPK or SPK Suspect under the same conditions. 
Figure 16 shows the total number of subjects and Figure 17 shows the 
percentage of subjects with SPK or SPK Suspect under the same conditions. 
The Bowker test of symmetry was performed for the data from each exam visit. 
Data were organized according to the order in which subjects completed the 
study, that is, 
AOSept in Phase I versus ReNu in Phase II and 
CONFIDENTIAL 
ReNu in Phase I versus AOSept in Phase II (see Table 7). 
Also included in Table 7 are the results of the statistical analyses for each 
Bowker array. Note that, based on the adjusted level of significance for these 
analyses, p = 0.1 25, only one array at the 4 Week exam visit demonstrates 
statistical significance, but the trend for all other arrays (other than the 
Dispensing visits) is in the same direction. In all cases, subjects who used ReNu 
were more likely to develop SPK or SPK Suspect. 
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None 
Susp 
SPK 
Table 6. Total number of patients exhibiting: 
no SPK (None), 
SPK Suspect (Susp), and 
SPK 
at each exam visit (Dispense, 1 Week, 2 Week, 4 Week) for each 
lens care regimen (AOSept or ReNu) throughout the two phases of 
the study. 
Dis~ensinq Visit 
RE / II AOSEPT 1 l RE / I AOSEPT / II 
None Susp SPK 
~ o n e i  16 1 0 1 
ChiA2 1.00 
df 3 
p 0.801 
1 Week Visit 
RE 1 II AOSEPT 1 I 
None Susp SPK 
None 1 8 0 01 
2 Week Visit 
RE I II AOSEPT / I 
Susp 
SPK 
3 2 0 
4 1 0 
n 18 
ChiA2 8.00 
df 3 
p 0.046 
None Susp SPK 
n 16 
ChiA2 6.80 
df 3 
p 0.079 
4 Week Visit 
RE I II AOSEPT 1 I 
None Susa SPK 
None 
Susp 
SPK 
susp 
SPK 
4 1 0 1 
4 1 0 
5 0 1 
N o n e e l  SUSP 
SPK 
n 16 
ChiA2 0.67 
df 3 
p 0.881 
RE / I AOSEPT / II 
SPK 
None p 
susp 
SPK 
n 15 
ChiA2 8.00 
df 3 
p 0.046 
RE11 AOSEPT / II 
None SUSD SPK 
SPK I 6 1 0 1 
n 15 
ChiA2 7.00 
df 3 
p 0.072 
None 
Susp 
RE I l AOSEPT I ll 
5 0 0 
1 1 1 
None Sus p SPK 
None I 3 0 0 1 
Table 7. Bowker arrays and statistical analyses comparing SPK categories 
at each exam visit (Dispensing, 1 Week, 2 Week, and 4 Week) for 
each lens care regimen throughout the two phases of the study: 
AOSept in Phase I [A0 I I] versus ReNu in Phase II [RE I Ill, 
and 
ReNu in Phase I [RE 1 I] versus AOSept in Phase II [A0 1 Ill, 
at each exam visit (Dispense, 1 Week, 2 Week, 4 Week). 
Susp 
SPK 
3 0 0 
10 2 0 
n 14 
ChiY 11.0 
df 3 
p 0.012 


Figure 16. Shows the total number of subiects with SPK or SPK Suspect for 
each care regimen and phase combination at each exam visit. 
Figure 17. Shows the percentaqe of subiects with SPK or SPK Suspect for 
each care regimen and phase combination at each exam visit. 
Summary: 
These data can be best summed up by individually reviewing the 5 indices of 
corneal staining used throughout the study; 
Type of corneal staining 
Depth of corneal staining 
Area of corneal staining 
lncidence of superficial punctate keratitis, suspect 
lncidence of superficial punctate keratitis 
A value was selected to represent "clinical significance" and the percent of 
subjects with clinically significant findings is reported. 
CORNEAL STAINING PATTERNS 
Type of Corneal Staining 
Throughout the study the type of corneal staining was graded on a 0 to 4 scale, 
with type 2 staining classified as macropunctate and considered a "clinical 
concern". At the dispensing visit, the percent of subjects with type 2 staining or 
greater was; 
Dispensing Visit Data N = 34 
Acuvue 2 Eye to Use ReNu MPS 5.88% 
Acuvue 2 Eye to Use AOSept 11.76% 
Soflens 66 Eye to Use ReNu MPS 8.82% 
Soflens 66 Eye to Use AOSept 14.71 % 
At the end of four weeks, the percent of subjects with type 2 staining or greater 
was; 
4 week Data N = 28 
Acuvue 2 Lens with ReNu MPS 50.00% 
Acuvue 2 Lens with AOSept 25.00% 
Soflens 66 with ReNu MPS 64.29% 
Soflens 66 with AOSept 7.14% 
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Depth of Corneal Staining 
Throughout the study the depth of corneal staining was graded on a 0 to 3 scale, 
with type 2 depth of staining classified as full epithelial staining and considered 
a "clinical concern". At the dispensing visit, the percent of subjects with type 2 
depth of staining or greater was: 
Dispensinq Visit Data N = 34 
Acuvue 2 Eye to Use ReNu MPS 5.88% 
Acuvue 2 Eye to Use AOSept 2.94% 
Soflens 66 Eye to Use ReNu MPS 5.88% 
Soflens 66 Eye to Use AOSept 5.88% 
At the 4 week visit, the percent of subjects with type 2 depth of staining or greater 
was; 
4 week Data N = 28 
Acuvue 2 Lens with ReNu MPS 39.29% 
Acuvue 2 Lens with AOSept 21.43% 
Soflens 66 with ReNu MPS 53.57% 
Soflens 66 with AOSept 7.14% 
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Area of Corneal Staining 
Throughout the study the area of corneal staining was graded on a 0% to 100% 
scale, with 30% area of staining considered a "clinical concern". At the 
dispensing visit, the percent of subjects with 30% area of staining or greater was: 
Dispensinq Visit Data N = 34 
Acuvue 2 Eye to Use ReNu MPS 0.00% 
Acuvue 2 Eye to Use AOSept 0.00% 
Soflens 66 Eye to Use ReNu MPS 0.00% 
Soflens 66 Eye to Use AOSept 0.00% 
At the 4 week visit, the percent of subjects with areas of staining 30% or greater 
was; 
4 week Data N = 28 
Acuvue 2 Lens with ReNu MPS 25.00% 
Acuvue 2 Lens with AOSept 3.57% 
Soflens 66 with ReNu MPS 53.53% 
Soflens 66 with AOSept 7.14% 
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Superficial Punctate Keratitis (Suspect) 
Throughout the study SPK Suspect was defined as: 
Type 1 staining in four quadrants of the cornea with no other type of staining 
in the fifth quadrant. 
Or 
Any type of staining in three quadrants. 
At the dispensing visit, the percent of subjects classified as superficial punctate 
keratitis suspects was; 
Dispensing Visit Data N = 34 
Group 1 Subjects to Use ReNu MPS 18.75% 
Group 2 Subjects to Use ReNu MPS 5.56% 
Group 1 Subjects to Use AOSept 11.11% 
Group 2 Subjects to Use AOSept 31.25% 
At the 4 week visit, the percent of subjects classified as superficial punctate 
keratitis suspects was; 
4 week Data N = 28 
Group I Subjects on ReNu MPS 14.29% 
Group 2 Subjects on ReNu MPS 42.86% 
Group 1 Subjects on AOSept 28.57% 
Group 2 Subjects on AOSept 7.14% 
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Superficial Punctate Keratitis (SPK) 
Throughout the study superficial punctate keratitis was defined as: 
Any type of staining in all five regions quadrants of the cornea, 
Any type of staining in at least three quadrants in addition to 
(type 2) in at least one quadrant 
(type 3) in at least one quadrant 
(type 4) in at least one quadrant 
At the dispensing visit, the percent of subjects classified as having superficial 
punctate keratitis was; 
Dispensinq Visit Data N = 34 
Group 1 Subjects to Use ReNu MPS 0.00% 
Group 2 Subjects to Use ReNu MPS 0.00% 
Group 1 Subjects to Use AOSept 0.00% 
Group 2 Subjects to Use AOSept 0.00% 
At the 4 week visit, the percent of subjects classified as having superficial 
punctate keratitis was; 
4 week Data N = 28 
Group 1 Subjects on ReNu MPS 64.4% 
Group 2 Subjects on ReNu MPS 42.86% 
Group 1 Subjects on AOSept 0.00% 
Group 2 Subjects on AOSept 0.00% 
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Combined Data 
At the dispensing visit, the percent of subjects classified as having superficial 
punctate keratitis or being a superficial punctate keratitis suspect was; 
Dispensinq Visit Data N = 34 
Group 1 Subjects to Use ReNu MPS 18.75% 
Group 2 Subjects to Use ReNu MPS 5.56% 
Group 1 Subjects to Use AOSept 11.11% 
Group 2 Subjects to Use AOSept 3 1.25% 
At the 4 week visit, the percent of subjects classified as having superficial 
punctate keratitis or being a SPK suspect was; 
4 week Data N =28 
Group 1 Subjects on ReNu MPS 78.57% 
Group 2 Subjects on ReNu MPS 85.71 % 
Group 1 Subjects on AOSept 28.57% 
Group 2 Subjects on AOSept 7.14% 
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These data clearly indicate that the incidence of corneal staining (with all five 
indices measured), 
type of corneal staining 
depth of corneal staining 
area of corneal staining 
incidence of superficial punctate keratitis, suspect 
incidence of superficial punctate keratitis 
was significantly greater when subjects used the ReNu Multipurpose Solution vs. 
AOSept. 
The most striking feature of the study was that after 4 weeks of use, 
55% of the subjects on ReNu MPS had clinically significant Superficial 
Punctate Keratitis where as, 
0% of the subjects using AOSept had SPK. 
Throughout the course of the study there was a definite trend towards greater 
corneal staining with the ReNu solution in subjects wearing Soflens 66 vs. 
Acuvue 2 lenses. While this number was not statistically significant the trend is 
reflected in the four week data related to the: 
Type of corneal staining (grade 2 or greater) 
Acuvue 2 on ReNu 50.00% 
Soflens 66 on ReNu 64.29% 
Depth of corneal staining (grade 2 or greater) 
Acuvue 2 on ReNu 39.29% 
Soflens 66 on ReNu 53.57% 
Area of Corneal Staining (30% or greater) 
Acuvue 2 on ReNu 25.00% 
Soflens 66 on ReNu 53.57% 
This might indicate a tendency towards greater corneal staining problems with 
the type 2 Soflens 66 vs. the type 4 Acuvue 2. 
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Technical Report 
Part I1 
Subjective Analysis 
Comparison of Corneal Staining With 
Soflens 66 and Acuvue 2 With 
AOSept and ReNu Multiplus Multipurpose 
Solution 
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Introduction 
Subjects wore each of two soft contact lens types, Soflens 66 and Acuvue 2, in 
either eye. The same contact lens type was worn in the same eye throughout the 
study. One of two lens care regimens, AOSept and ReNu, was used during 
Phase I, and the other was used during Phase II. Subjects were randomly 
divided into groups such that approximately half wore each contact lens type on 
one eye, while the other half wore the second contact lens type on the fellow eye, 
and also such that approximately half used one lens care regimen during Phase 
I, while the other half used the second lens care regimen. Subjects switched lens 
care regimens for Phase II, but all other factors remained the same. 
Subjects were questioned about the contact lenses 30 minutes after initial 
insertion during the dispensing visit at the start of each phase, and again at the 
I-week, 2-week, and 4-week follow-up visits during each phase. At the 
dispensing visit, subjects were asked to assess their near vision, distance vision, 
and overall vision for each eye, as well as the comfort, dryness, grittiness, and 
ease of insertion of each contact lens. Evaluations were made on a five-point 
scale, with 5 indicating "excellent" performance or no occurrence (based on the 
question) and 1 indicating "poor" performance or constant occurrence. These 
questions were asked again at the follow-up visits. In addition, at the follow-up 
visits, subjects were asked to assess burning on first insertion, ease of removal, 
and ease of handling of each contact lens. Subjects also were asked about 
average daily wear time and nightly soak time of the contact lenses since the last 
visit, and wear time on the day of the visit. 
Statistical Analyses 
Responses to all subjective questions were evaluated using the multidimensional 
chi-square (X2) analysis (Sheskin, 2000). This is a non-parametric test of 
population differences where multiple dependent or independent factors may 
influence the results. Analyses were considered significant at the 0.05 level. 
Dispensing Visit 
For the dispensing visit questions, the factors under consideration include 
- the contact lens worn (Acuvue 2 or Soflens 66); 
- the eye used with each contact lens type (OD or 0s ) ;  and 
- the phase of the study. 
We do not expect the latter two factors to produce any significant differences in 
the responses, as participation in Phase I should not influence responses in 
Phase Ill and as responses should not depend on which eye wears a particular 
contact lens. However, there could be potential differences between the contact 
lens types, as well as interaction effects of the factors, for the questions asked 
during the dispensing visit. 
CONFIDENTIAL 
Table 1 shows the data regarding the initial comfort of each contact lens. There 
are no significant differences in responses based on the main effects of 
- phase, x2(3) = 0.40, p = 0.939; 
- eye, ~ ' (3 )  = 3.46, p = 0.326; or 
- contact lens, ~ ' ( 3 )  = 4.98, p = 0.173, 
nor those based on any interaction effects of 
- contact lens and phase, x2(9) = 8.23, p = 0.51 1 ; 
- eye and phase, x2(9) = 3.91, p = 0.917; 
- eye and contact lens, X2(9) = 10.20, p = 0.338; or 
- phase, eye, and contact lens, ~'(25) = 16.1, p = 0.913. 
Table 1. Tabulation of responses for initial comfort of the contact lens. 5 = 
excellent, 1 = poor. OD = right eye, OS = left eye. 
Table 2 shows the data regarding the initial dryness of each contact lens. There 
are no significant differences in responses based on the main effects of 
- phase, x2(3) = 2.62, p = 0.454; 
- eye, X2(3) = 1 .I 6, p = 0.763; or 
- contact lens, x2(3) = 1.16, p = 0.763, 
nor those based on any interaction effects of 
- contact lens and phase, x2(9) = 4.94, p = 0.840; 
- eye and phase, x2(9) = 5.79, p = 0.761 ; 
- eye and contact lens, x2(9) = 6.35, p = 0.705; or 
- phase, eye, and contact lens, ~'(25) = 16.0, p = 0.916. 
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Table 2. Tabulation of responses for initial dryness of the contact lens. 5 = never, 
1 = constant. OD = right eye, OS = left eye. 
Table 3 shows the data regarding the initial grittiness of each contact lens.  here 
are no significant differences in responses based on the main effects of 
- phase, x2(3) = 1.20, p = 0.754; 
- eye, x2(3) = 1.20, p = 0.754; or 
- contact lens, x2(3) = 2.34, p = 0.505, 
nor those based on any interaction effects of 
- contact lens and phase, ~ ' (9 )  = 5.55, p = 0.784; 
- eye and phase, ~ ' (9 )  = 3.53, p = 0.939; 
- eye and contact lens, x2(9) = 6.52, p = 0.687; or 
- phase, eye, and contact lens, ~ ' (25) = 15.3, p = 0.933. 
Table 3. Tabulation of responses for initial grittiness of the contact lens. 5 = 
never, 1 = constant. OD = right eye, OS = left eye. 
Table 4 shows the data regarding near vision with each contact lens. There are 
no significant differences in responses based on the main effects of 
- phase, ~ ' (2 )  = 0.37, p = 0.832; 
- eye, ~ ' ( 2 )  = 1.14, p = 0.566; or 
- contact lens, ~ ' ( 2 )  = 0.47, p = 0.790, 
nor those based on any interaction effects of 
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- contact lens and phase, x2(6) = 1 -20, p = 0.977; 
- eye and phase, x2(6) = 3.42, p = 0.754; 
- eye and contact lens, ~ ~ ( 6 )  = 6.42, p = 0.378; or 
- phase, eye, and contact lens, ~ ~ ( 1  8) = 1 .6, p = 0.868. 
Table 4. Tabulation of responses for near vision with the contact lens. 5 = 
excellent, 1 = poor. OD = right eye, OS = left eye. 
Table 5 shows the data regarding distance vision with each contact lens. There 
are no significant differences in responses based on the main effects of 
- phase, x2(3) = 3.46, p = 0.326; 
- eye, x2(3) = 0.68, p = 0.877; or 
- contact lens, ~ ~ ( 3 )  = 6.93, p = 0.074, 
nor those based on any interaction effects of 
- contact lens and phase, x2(9) = 10.9, p = 0.284; 
- eye and phase, ~ ~ ( 9 )  = 5.75, p = 0.764; 
- eye and contact lens, ~ ' ( 9 )  = 10.6, p = 0.304; or 
- phase, eye, and contact lens, x2(25) = 20.4, p = 0.726. 
Table 5. Tabulation of responses for distance vision with the contact lens. 5 = 
excellent, 1 = poor. OD = right eye, OS = left eye. 
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Table 6 shows the data regarding overall vision with each contact lens. There are 
no significant differences in responses based on the main effects of 
- phase, x2(2) = 4.36, p = 0.1 13; 
- eye, x2(2) = 2.61, p = 0.271; or 
- contact lens, ~ ' ( 2 )  = 2.61, p = 0.271, 
nor those based on any interaction effects of 
- contact lens and phase, x2(6) = 7.53, p = 0.274; 
- eye and phase, x2(6) = 7.53, p = 0.274; 
- eye and contact lens, ~ ' (6 )  = 7.47, p = 0.279; or 
- phase, eye, and contact lens, x2(18) = 17.3, p = 0.505 
Table 6. Tabulation of responses for overall vision with the contact lens. 5 = 
excellent, 1 = poor. OD = right eye, OS = left eye. 
Table 7 shows the data regarding the ease of insertion of each contact lens. 
There is a significant difference in responses based on the main effect of 
- contact lens, ~ ' (3 )  = 14.2, p = 0.003, 
and on the interaction effects of 
- contact lens and phase, x2(9) = 22.2, p = 0.008; and 
- eye and contact lens, X2(9) = 21.9, p = 0.009. 
However, there are no significant differences in responses based on the main 
effects of 
- phase, x2(3) = 6.14, p = 0.105; or 
- eye, x2(3) = 2.83, p = 0.419, 
nor on the interaction effects of 
- eye and phase, x2(9) = 9.02, p = 0.435; and 
- phase, eye, and contact lens, x2(25) = 33.8, p = 0.1 12. 
The analysis indicates that subjects had more difficulty inserting the Soflens 66 
contact lens, especially during Phase II, where the weighted-average responses 
for the right and left eyes were 4.00 and 4.08, respectively, compared to 
weighted-average responses that range from 4.38 to 4.93 under the other 
conditions. 
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Table 7. Tabulation of responses for ease of insertion of the contact lens. 5 = 
easy, I = impossible. OD = right eye, OS = let3 eye. Mean Wt = weighted 
average. 
The analyses of the dispensing visit data confirm the hypothesis that there are no 
significant differences in subjective performance based on which contact lens 
was worn in which eye, nor on which phase of the study the subjects were in. 
Therefore, the follow-up data may be evaluated without regard to the study 
phase and which eye wore which contact lens. 
Follow-Up Visits 
For the follow-up visit questions, the factors under consideration include 
- the lens care regimen used (AOSept or ReNu); 
- the contact lens worn (Acuvue 2 or Soflens 66); and 
- the exam visit of the follow-up (1 week, 2 weeks, or 4 weeks). 
Table 8 shows the data regarding the overall comfort of each contact lens since 
the last visit. There are significant differences in responses based on the main 
effects of 
- lens care regimen, x2(4) = 16.6, p = 0.002; and 
- exam visit, x2(8) = 21.9, p = 0.005, 
and on the interaction effects of 
- contact lens and lens care regimen, x2(12) = 24.2, p = 0.019; 
- lens care regimen and exam visit, ~'(20) = 49.8, p = 0.000; and 
- contact lens and exam visit, X2(20) = 33.0, p = 0.034. 
However, there are no significant differences in responses based on the main 
effect of 
- contact lens, x2(4) = 6.79, p = 0.147, 
nor on the overall interaction effect of 
- lens care regimen, contact lens, and exam visit, x2(51) = 64.4, p = 0.099. 
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Table 8. Tabulation of responses for overall comfort of the contact lens since the 
last visit. 5 = excellent, 1 = poor. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 4 
weeks. Mean Wt = weighted average. 
The analysis indicates that overall comfort of the contact lens decreases over 
time, regardless of which contact lens is worn or which lens care regimen is 
used. Nonetheless, as demonstrated by the significant interaction effects, the 
weighted-average responses for AOSept are consistently higher than those for 
ReNu (regardless of contact lens), and those for Acuvue- 2 are consistently 
higher than those for Soflens 66 (regardless of lens care regimen). 
Table 9 shows the data regarding the overall dryness of each contact lens since 
the last visit. There are significant differences in responses based on the main 
effect of 
- lens care regimen, ~ ' ( 4 )  = 15.8, p = 0.003, 
and on the interaction effect of 
- lens care regimen and exam visit, ~ ~ ( 2 0 )  = 34.2, p = 0.025. 
However, there are no significant differences in responses based on the main 
effects of 
- contact lens, X2(4) = 1.82, p = 0.789; or 
- exam visit, ~ ~ ( 8 )  = 10.9, p = 0.205, 
nor on the interaction effects of 
- contact lens and lens care regimen, ~ ~ ( 1 2 )  = 19.0, p = 0.088; 
- contact lens and exam visit, ~ ~ ( 2 0 )  = 16.2, p = 0.704; or 
- lens care regimen, contact lens, and exam visit, ~ ' (51) = 44.9, p = 0.713. 
The analysis indicates that overall dryness is more noticeable, and worsens over 
time, with ReNu (regardless of contact lens). 
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Table 9. Tabulation of responses for overall dryness of the contact lens since the 
last visit. 5 = never, 1 = constant. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 4 
weeks. Mean Wt = weighted average. 
Table 10 shows the data regarding the overall grittiness of each contact lens 
since the last visit. There is a significant difference in responses based on the 
main effect of 
- lens care regimen, ~ ' ( 4 )  = 10.4, p = 0.034. 
However, there are no significant differences in responses based on the main 
effects of 
- contact lens, ~ ' ( 4 )  = 1.49, p = 0.828; or 
- exam visit, ~ ' ( 8 )  = 13.0, p = 0.1 11, 
nor on the interaction effects of 
- contact lens and lens care regimen, x2(1 2) = 12.1, p = 0.440; 
- lens care regimen and exam visit, ~'(20) = 25.6, p = 0.1 79; 
- contact lens and exam visit, ~'(20) = 18.2, p = 0.572; or 
- lens care regimen, contact lens, and exam visit, ~ ' (51) = 32.5, p = 0.980. 
The analysis indicates that overall grittiness is more noticeable with ReNu 
(regardless of contact lens and length of use). 
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Table 10. Tabulation of responses for overall grittiness of the contact lens since 
the last visit. 5 = never, I = constant. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 4 
weeks. Mean Wt = weighted average. 
Table 11 shows the data regarding near vision with each contact lens since the 
last visit. There is a significant difference in responses based on the main effect 
of 
- contact lens, ~ ' ( 4 )  = 9.61, p = 0.048. 
However, there are no significant differences in responses based on the main 
effects of 
- lens care regimen, ~ ' ( 4 )  = 6.92, p = 0.140; or 
- exam visit, ~ ~ ( 8 )  = 7.26, p = 0.509, 
nor on the interaction effects of 
- contact lens and lens care regimen, ~ ~ ( 1 2 )  = 17.4, p = 0.135; 
- lens care regimen and exam visit, ~ ~ ( 2 0 )  = 24.1, p = 0.238; 
- contact lens and exam visit, ~ ~ ( 2 0 )  = 20.8, p = 0.408; or 
- lens care regimen, contact lens, and exam visit, X2(51) = 40.9, p = 0.842. 
The analysis indicates that near vision is consistently poorer with Soflens 66 
(regardless of lens care regimen and length of use). 
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Table 1 I. Tabulation of responses for near vision with the contact lens since the 
last visit. 5 = excellent, 1 = poor. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 4 
weeks. Mean Wt = weighted average. 
Table 12 shows the data regarding distance vision with each contact lens since 
the last visit. There are significant differences in responses based on the main 
effect of 
- contact lens, x2(4) = 16.5, p = 0.002, 
and on the interaction effect of 
- contact lens and lens care regimen, ~ ~ ( 1 2 )  = 27.9, p = 0.006. 
However, there are no significant differences in responses based on the main 
effects of 
- lens care regimen, ~ ~ ( 4 )  = 8.90, p = 0.064; or 
- exam visit, x2(8) = 12.5, p = 0.132, 
nor on the interaction effects of 
- lens care regimen and exam visit, ~ ~ ( 2 0 )  = 27.8, p = 0.1 13; 
- contact lens and exam visit, ~ ' (20) = 31.2, p = 0.053; or 
- lens care regimen, contact lens, and exam visit, X2(51) = 51 .I, p = 0.470. 
The analysis indicates that distance vision is consistently poorer with Soflens 66, 
especially when used with ReNu. The trend of the weighted-average responses 
implies worsening of distance vision over time (regardless of lens care regimen 
or contact lens), although this is not supported by the statistical analysis. 
CONFIDENTIAL 
Table 12. Tabulation of responses for distance vision with the contact lens since 
the last visit. 5 = excellent, I = poor. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 4 
weeks. Mean Wt = weighted average. 
Table 13 shows the data regarding the overall vision with each contact lens since 
the last visit. There are significant differences in responses based on the main 
effects of 
- lens care regimen, x2(4) = 10.5, p = 0.033; and 
- contact lens, ~ ' ( 4 )  = 16.8, p = 0.002, 
and on the interaction effects of 
- contact lens and lens care regimen, X2(12) = 27.8, p = 0.006; and 
- contact lens and exam visit, ~'(20) = 32.4, p = 0.039. 
However, there are no significant differences in responses based on the main 
effect of 
- exam visit, ~ ' (8 )  = 12.0, p = 0.152, 
nor on the interaction effects of 
- lens care regimen and exam visit, ~'(20) = 29.4, p = 0.080; or 
- lens care regimen, contact lens, and exam visit, X2(51) = 53.6, p = 0.376. 
Table 13. Tabulation of responses for overall vision with the contact lens since 
the last visit. 5 = excellent, I = poor. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 4 
weeks. Mean Wt = weighted average. 
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The analysis indicates that overall vision is consistently poorer with Soflens 66, 
especially when used with ReNu. There is also a worsening of overall vision over 
time, when considered in conjunction with the contact lens, as evidenced by the 
significant "contact lens and exam visit" interaction effect. 
Table 14 shows the data regarding the sensation of burning on first insertion of 
each contact lens since the last visit. There are no significant differences in 
responses based on the main effects of 
- lens care regimen, x2(4) = 2.94, p = 0.568; 
- contact lens, x2(4) = 1.07, p = 0.899; or 
- exam visit, x2(8) = 8.54, p = 0.383, 
nor on the interaction effects of 
- contact lens and lens care regimen, x2(12) = 5.76, p = 0.928; 
- lens care regimen and exam visit, x2(20) = 16.5, p = 0.685; 
- contact lens and exam visit, x2(20) = 10.7, p = 0.954; or 
- lens care regimen, contact lens, and exam visit, x2(51) = 26.2, p = 0.998. 
Table 14. Tabulation of responses for sensation of burning on first insertion of the 
contact lens since the last visit. 5 = never, 1 = constant. 1 WK = 1 week, 2 WK = 
2 weeks, 4 WK = 4 weeks. Mean Wt = weighted average. 
Table 15 shows the data regarding the ease of insertion of each contact lens 
since the last visit. There are significant differences in responses based on the 
main effect of 
- contact lens, x2(4) = 23.5, p = 0.000, 
and on the interaction effects of 
- contact lens and lens care regimen, x2(12) = 26.7, p = 0.008; and 
- contact lens and exam visit, x2(20) = 34.8, p = 0.021. 
However, there are no significant differences in responses based on the main 
effects of 
- lens care regimen, x2(4) = 2.02, p = 0.732; or 
- exam visit, x2(8) = 7.09, p = 0.527, 
nor on the interaction effects of 
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- lens care regimen and exam visit, x2(20) = 11.9, p = 0.91 9; or 
- lens care regimen, contact lens, and exam visit, x2(51) = 52.1, p = 0.432. 
The analysis indicates that contact lens insertion is consistently more difficult with 
Soflens 66. 
Table 15. Tabulation of responses for ease of insertion of the contact lens since 
the last visit. 5 = easy, 1 = impossible. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 
4 weeks. Mean Wt = weighted average. 
Table 16 shows the data regarding the ease of removal of each contact lens 
since the last visit. There are no significant differences in responses based on 
the main effects of 
- lens care regimen, x2(2) = 3.45, p = 0.178; 
- contact lens, x2(2) = 0.14, p = 0.933; or 
- exam visit, ~ ' ( 4 )  = 3.94, p = 0.41 5, 
nor on the interaction effects of 
- contact lens and lens care regimen, x2(6) = 4.44, p = 0.618; 
- lens care regimen and exam visit, x2(10) = 8.81, p = 0.550; 
- contact lens and exam visit, x2(10) = 4.1 5, p = 0.940; or 
- lens care regimen, contact lens, and exam visit, ~ '(29) = 11.2, p = 0.999. 
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Table 16. Tabulation of responses for ease of removal of the contact lens since 
the last visit. 5 = easy, 1 = impossible. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 
4 weeks. Mean Wt = weighted average. 
Table I 7  shows the data regarding the overall handling of each contact lens 
since the last visit. There are significant differences in responses based on the 
main effect of 
- contact lens, ~ ' (4 )  = 17.7, p = 0.001, 
and on the interaction effects of 
- contact lens and lens care regimen, ~ ' (12) = 23.3, p = 0.025; and 
- contact lens and exam visit, ~'(20) = 33.7, p = 0.028. 
However, there are no significant differences in responses based on the main 
effects of 
- lens care regimen, ~ ' ( 4 )  = 4.21, p = 0.378; or 
- exam visit, ~ ' (8 )  = 10.2, p = 0.252, 
nor on the interaction effects of 
- lens care regimen and exam visit, x2(20) = 19.4, p = 0.496; or 
- lens care regimen, contact lens, and exam visit, X2(51) = 48.9, p = 0.557. 
The analysis indicates that overall handling is consistently poorer with Soflens 
66. 
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Table 17. Tabulation of responses for overall handling of the contact lens since 
the last visit. 5 = excellent, 1 = poor. 1 WK = 1 week, 2 WK = 2 weeks, 4 WK = 4 
weeks. Mean Wt = weighted average. 
Table 18 shows the average daily wear time, nightly soak time, and wear time on 
day of visit with each lens care regimen. Also shown are standard deviations and 
minimum and maximum reported times. There are no significant differences for 
any of these values based on lens care regimen or time in the study. 
Table 18. Average daily wear time, nightly soak time, and wear time on day of 
visit with each lens care regimen, all in hours. n = number of subjects, s.d. = 
standard deviation, min = minimum report time, max = maximum reported time. 
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Appendix A 
Study Forms 
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E n r o l l m e n t  V i s i t  
Patient: Date: 
Phone #: Email: 
Patient History: 
CURRENT LENSES: 
Habitual Solutions (Brand) 
Habitual Lens Replacement Schedule: 
Habitual Wearing Time Per Day: h rs 
Patient Has Been Out of CLs: hrs 
OD DIM ENS^ 0s 
BASE CURVE 
INITIAL EXAM1 NATION 
Manifest Refraction: OD - - 
- 
- 
Distance VA's with Refraction: 
POWER 
DIAMETER 
BRAND 
OD: 201 0s: 201 
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SLIT LAMP EXAMINATION 
FLUORESCEIN STAINING 
4: Patch (>= I mm) 
-(record in full units only) 
0: 0% 1 : 10% 2: 20% 
3: 30% 4: 40% 5: 50% 
6: 60% 7: 70% 8: 80% 
9: 90% 10: 100% 
1: Superficial Epithelial 
2: Full Epithelial 
3: Stromal Glow 
Keratometry: OD: @ I @ 
Horizontal Visible Iris Diameter: OD: mm 
0 s :  mm 
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ORDER LENSES: 
BASE CURVE 
POWER 
DIAMETER 
BRAND 
# BOXES 
Read and Sign Informed Consent? Yes No 
Remind Patient to Discontinue Current Lens Use 2 Days Prior to Dispensing Visit 
Schedule Dispensing Visit: Date: Time: 
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D i s p e n s i n g  V i s i t  
Patient: Date: 
Length of Time Patient has discontinued SCL wear: days 
SLIT LAMP EXAMINATION 
FLUORESCEIN STAINING 
4: Patch (>= Imm) 
-(record in full units only) 
O:O% 1:10% 2:20% 
9: 90% 10: 100% 
(record in full units 
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DISPENSED SCLs: 
Dispensed Solutions: B&L ReNu Multiplus Multipurpose Solution 
Ciba AOSept 
OD 
Distance VA1s with SCLs: OD: 201 0 s :  201 
Remind Patient: 
1. Do not mix up the lenses 
2. Follow the patient lens care protocol as outlined 
3. Wear contact lenses a minimum of 10 hours per day 
4. Store lenses overnight a minimum of 8 hours 
5 .  Immediately report any abnormalities (i.e. ocular complications, lost or 
damaged lenses, etc.) to the investigators andlor monitors 
DIAMETER 
BRAND 
DIMENSIONS 
BASE CURVE 
POWER 
Schedule Follow Up Visit: Date: Time: 
0s 
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F o l l o w - U p  V i s i t  
Patient: 
Follow-up Visit: One Week Two Week 
CURRENT LENSES: 
Date: 
Four Week 
OD DIMENSIONS 0s 
BASE CURVE 
POWER 
DIAMETER 
BRAND 
Present Solutions: B&L ReNu Multiplus Multipurpose Solution 
Ciba AOSept 
Subjective Symptoms: 
Distance VA's with SCLs: OD: 201 0s: 201 
Slit Lamp Examination: 
Are the SCLs on the appropriate eyes? Yes 
SLIT LAMP EXAMINATION 
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FLUORESCEIN STAINING 
Supplemental Testing: 
Slit Lamp Photography? 
Video Photography? 
Instruct Patient to: 
1. Continue to wear present SCL 
*** IMPORTANT: DO NOT DISPOSE OF SCL UNTIL AFTER WEEK FOUR VISIT *** 
2. Continue present lens care solutions 
3. Return to clinic in one week 
Next Follow-up Visit: Date: Time: 
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Appendix B 
Lens Care Instructions 
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Instructions for CIBA-Vision AOSEPT Solution 
Directions: TO OBTAIN CLEANING AND DISINFECTION, THESE STEPS 
MUST BE COMPLETED: 
Step 1 - Cleaning lenses after removal 
Clean the surface of the right lens with MiraFlow Extra-Strength Daily 
Cleaner. 
A Rinse the lens thoroughly with a steady stream of sterile saline solution 
(CIBA-Vision Saline or SoftWear Saline and place the right lens on the 
dome in the appropriate side of the lens holder. On the AOSEPT Lens 
Cup, the right side is unmarked. On the AOSEPT Disposable Cup and 
Disc, the right side is marked "R". 
-I Repeat the first two steps with the left lens and place the lens on the 
other dome of the lens holder. 
-I To prevent damage to your lens, center the lens on the dome in the 
lens holder. Be sure the lens does not tough the basket rim, then 
close the basket lid. 
Step 2 - DisinfectionlNeutralization of the lenses 
An AODISC must always be present to neutralize the AOSEPT 
Disinfectant. Place the AODISC onto the stem. If using the AOSEPT 
Disposable Cup and Disc, the lens cup contains a built-in platinum 
coated Neutralizer Disc. 
-I After you have placed your lenses in the lens holder, fill the cup with 
AOSEPT Disinfectant to the fill line and place the lens holder in the 
cup. Tighten the cap (clockwise). DO NOT OVERFILL. Overfilling the 
cup will cause the AOSEPT Disinfectant to overflow from the cup. 
Allow the lenses to soak for a minimum of 6 hours or overnight. 
After a minimum of 6 hours, your lenses are disinfectedlneutralized. If 
your lenses have been soaking in the cup for more than 24 hours, 
you must repeat the disinfectionlneutralization procedure again 
before wearing your lenses. 
A You must rinse each lens thoroughly with a sterile saline such as ClBA 
Vision Saline or SoftWear Saline prior to lens insertion on the eye. 
-I After putting your lenses on, always discard the neutralized AOSEPT 
Disinfectant from the lens cup, rinse with AOSEPT Disinfectant, ClBA 
Vision Saline or SoftWear Saline and leave the cup open to air dry. 
This rinsing and air drying will help to keep your cup free of microbial 
contaminants. The lens holder should be inverted (outside of the cup) 
so it is not lying on the side. 
Replacement Schedule: 
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A The AODISC and AOSEPT Disinfectant Cup and Disc must be 
replaced after 100 uses or 3 months of daily use. 
A To minimize the risk of microbial contamination of the AOSEPT Lens 
Cup, it is recommended that you replace your AOSEPT Lens Cup 
every 6 months. 
Direction Notes: 
A If bubbles leak from the hole on the top of the cap of the lens holder, 
this indicates that you have overfilled the cup or that you may not have 
thoroughly rinsed the cleaner off your lenses. 
-I Never rinse your lenses with AOSEPT Disinfectant and put directly into 
your eye. 
A Lenses must always be disinfectedlneutralized for a minimum of 6 
hours in the AOSEPT Disposable Cup and Disc or in AOSEPT 
Lens Cup with the AODISC Neutralizer and rinsed with fresh 
saline before putting your lenses on. 
A Enzymatic cleaning of your lenses is not called for during the process 
of this study. 
*If you have any questions regarding the care of your contact lenses with this 
solution, a detailed insert is provided inside the carton of this solution, or you 
may contact the researchers at any time with your questions 
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Instructions for ReNu MultiPlus Multi-Purpose Solution 
Directions: TO OBTAIN CLEA NlNG AND DISINFECTION, THESE STEPS 
MUST BE COMPLETED: 
STEP 1 
A Place at least three drops of ReNu Multiplus solution on each side of 
the contact lens and rub for 20 seconds. 
STEP 2 
Remove surface debris by rinsing thoroughly with ReNu Multiplus 
solution. 
STEP 3 
A Place cleaned contact lenses in lens case and fill with fresh ReNu 
Multiplus solution. SOAK FOR AT LEAST FOUR HOURS. 
Your lenses are now ready to wear. No saline rinse is necessary. If any debris 
remains on contact lenses, rinse with ReNu Multiplus solution prior to insertion. 
If not wearing contact lenses immediately, store in close lens case. Do not store 
your lenses in ordinary saline in place of ReNu Multiplus solution. Saline solution 
will not disinfect. 
The use of a protein removal system is not needed with these lenses. 
Precautions: 
A Never re-use this solution. 
A Store at room temperature. 
-I Keep the bottle rightly closed when not in use. 
I- Keep out of the reach of children. 
Handle your lenses with the fingertips, avoid use of fingernails. 
When using hair spray, apply before lenses are inserted. 
A When using eye make up, apply after lenses are inserted. 
A Lenses should be cleaned and disinfected daily or after each wearing 
period. 
A Clean and disinfect one lens at a time to avoid mixing up left and right 
lenses. 
A To avoid contamination, don't touch tip of container to any surface and 
replace cap after using solution. 
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*If you have any questions regarding the care of your contact lenses with this 
solution, a detailed insert is provided on the inside carton of this solution, or you 
may contact the researchers at any time with your questions. 
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Appendix C 
Soft Contact Lens Disinfection 
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SOFT CONTACT LENS DISINFECTION, 
PAST and PRESENT 
Since soft contact lenses were introduced in the early 1970's the quest for daily 
lens disinfection products which are safe, effective and economical has been a 
slow evolutionary process. Today, all soft contact lens care systems can be 
classified into one of four categories: 
1. heat 
2. hydrogen peroxide 
3. chemical 
4. ultraviolet 
HEAT DISINFECTION 
Heat disinfection was introduced in 1971 as the first commercial technique for 
daily soft lens disinfection. Throughout the years heat disinfection has become 
the "gold standard" for soft lens disinfection in that it is the most effective system 
for eradicating microorganisms for soft contact lenses. 
The heat disinfection process begins with a 20- second in-the-palm cleaning and 
rinsing procedure. The lenses are placed into the appropriate storage case 
which is filled with fresh saline solution. The case is then placed into a heat 
disinfection unit and exposure to a temperature of 80 degrees centigrade for a 
period of ten minutes. This is followed by a 35 minute "cooling off' period and 
the disinfection process is completed. 
Although heat disinfection has many advantages it also has many disadvantages 
which include: 
1. The presence of a working electrical outlet of the appropriate voltage. 
2. polymer deterioration secondary to daily exposure to the 80' C temperature. 
3. more rapid denaturing "cooking on" of proteins present within and on the 
surfaces of the lenses. 
4. unit malfunction in which the required temperature for disinfection is not 
achieved or sustained. 
5. inability of the unit to automatically shut off following disinfection. 
For these reasons heat disinfection is rarely used today. 
CHEMICAL DISINFECTION 
The history of chemical disinfection for soft contact lenses dates back to 1977 
with the introduction of the Flexsol System by Burton Parson. The system 
consisted of three separate solutions for cleaning, rinsing and disinfection. This 
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was later replace by a two step system consisting of a surfactant cleaner and a 
rinsingldisinfection solution. Today, chemical disinfection systems are all multi- 
functional in that one solution is used to perform the cleaning, rinsing and 
disinfection procedures. These systems are commonly referred to as multi- 
purpose solutions and are by far the most commonly used technique for soft lens 
disinfection. Multi-purpose solutions offer the advantages of simplicity and 
convenience however, the potential exists for hypersensitivity reactions and 
increased epithelial staining. 
HYDROGEN PEROXIDE DISINFECTION 
Hydrogen peroxide has been used as an effective antimicrobial agent for over 
100 years. The first commercially available hydrogen peroxide disinfection 
system for soft contact lenses (LensSept) was introduced in 1983. 
Concentrations of .005 to .006% or 50 to 60 ppm (parts per million) are effective 
as a preservative whereas 3% or 30,000 ppm is required for disinfection. Today 
all hydrogen peroxide disinfection systems use 3% hydrogen peroxide. In 
general, the disinfection efficacy of 3% hydrogen peroxide is a function of time- 
of-contact in that the longer the better. A 3% concentration of hydrogen peroxide 
is cidal for a wide range of bacteria and viruses with a relatively short exposure 
time of 10 minutes however, longer exposures (up to 60 minutes) are required for 
adequate disinfection of most fungi. 
The hydrogen peroxides differ among themselves mainly in the method of 
neutralizing the residual peroxide in the lenses. The goal of hydrogen peroxide 
Neutralization is to: 
1. bring the concentration down to less than 50 to 60 ppm. 
2. adjust the pH to neutral (7.0 to 7.4) 
3. bring the tonicity close to isotonic (equal to 0.9% NaCI. 
Today, various methods are used to accomplish the neutralization goals. 
1. Rinsing 1 dilution: This neutralization consists of multiple saline rinses and 
soaks to dilute the hydrogen peroxide. This was the earliest technique for 
soft lens disinfection (late 1960's) and probably the least effective in that, high 
amounts of residual peroxide frequently remain. 
2. Catalytic disc: Exposure of hydrogen peroxide to a platinum-covered disc 
catalyzes (speeds-up) the dissociation of hydrogen peroxide into oxygen and 
water. This method provides good neutralization however, the age and 
condition of the disc are important factors. Therefore periodic replacement of 
the disc (every 3 month) is necessary. Additionally, the small surface area of 
the catalytic disc causes the neutralization process to be slow, approximately 
6 hours. 
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3. Sodium Pyruvate and Sodium Thiosulfate: These chemicals provide for a 
rapid means of hydrogen peroxide neutralization. However, a second rinse is 
often required to further dilute the peroxide. 
4. Catalase: Catalase is found in most animal cells where it neutralizes 
naturally-occurring hydrogen peroxide. Catalase is an extremely fast and 
effective neutralizer and is available in either liquid or tablet form. 
ULTRAVIOLET DISINFECTION 
It has been know for over a century that the ultraviolet wavelengths generated by 
the sun have significant germicidal effects. This form of radiant energy induces 
photochemical reactions within the molecules microorganisms which inhibit cell 
growth, and in higher dose result in microbial cell death. 
Studies have shown that a low discharge lamp generating UV-C light at 253.7 nm 
can effectively destroy bacteria, viruses, fungi, molds, yeasts and algae. In 1999 
the FDA approved the first soft lens care regime (PuriLens) to utilize UV-C light 
for disinfection. 
The three major components of the PuriLens System are; a UV generating lamp, 
a subsonic agitation cleaning mechanism and preservative free saline. The 
disinfecting and cleaning cycle is automatically activated when the top is placed 
onto the unit and the unit automatically shuts off at the end of the 15 minute 
disinfection cycle. In-the-palm digital cleaning is replaced by a significantly more 
effective 3600 cycles per minute subsonic agitation mechanism built into the unit. 
UV disinfection may replace heat and hydrogen peroxide as the method of 
choice for patients that require a simple, inexpensive form of preservative free 
disinfection. This is especially true in individuals wearing lens designs not yet 
available in a daily disposable modality. 
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